Investigation of plume dynamics during picosecond laser ablation of H13 steel using high-speed digital holography

Ablation of H13 tool steel using pulse packets with repetition rates of 400 and 1000 kHz and pulse energies of 75 and 44μJ, respectively, is investigated. A drop in ablation efficiency (defined here as the depth per pulse or μm/μJ) is shown to occur when using pulse energies of E$_{pulse}$>44μJ, accompanied by a marked difference in crater morphology. A pulsed digital holographic system is applied to image the resulting plumes, showing a persistent plume in both cases. Holographic data are used to calculate the plume absorption and subsequently the fraction of pulse energy arriving at the surface after traversing the plume for different pulse arrival times. A significant proportion of the pulse energy is shown to be absorbed in the plume for E$_{pulse}$>44μJ for pulse arrival times corresponding to > 1 MHz pulse repetition rate, shifting the interaction to a vapour-dominated ablation regime, an energetically costlier ablation mechanism.This work was collaboratively carried out under EPSRC Grant Number EP/K030884/1, as part of the EPSRC Centre for Innovative Manufacturing in Laser-based Production Processes. One of the authors acknowledges his PhD studentship by the Federal Government of Nigeria (TETFUND) in conjunction with the Federal University of Petroleum Resources Effurun (FUPRE)

Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma

Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared to circulating tumor cells (CTCs). We sought to investigate the potential of CHCs as a prognostic biomarker in uveal melanoma. Methods: We isolated peripheral blood monocular cells from uveal melanoma patients at the time of primary treatment and used antibodies against leukocyte and melanoma markers to identify and enumerate CHCs and CTCs by immunocytochemistry. Results: Using a multi-marker approach to capture the heterogeneous disseminated tumor cell population, detection of CHCs was highly sensitive in uveal melanoma patients regardless of disease stage. CHCs were detected in 100% of stage I-III uveal melanoma patients (entire cohort, n = 68), whereas CTCs were detected in 58.8% of patients. CHCs were detected at levels statically higher than CTCs across all stages (p = 0.05). Moreover, CHC levels, but not CTCs, predicted 3 year progression-free survival (p p < 0.04). Conclusion: CHCs are a novel and promising prognostic biomarker in uveal melanoma